



Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

Bernard G. Combe · Yoshiya Tanaka · Maya H. Buch · Peter Nash · Gerd R. Burmester · Alan J. Kivitz · Beatrix Bartok · Alena Pechonkina · Katrina Xia · Kahaku Emoto · Shungo Kano · Thijs K. Hendriks · Robert B. M. Landewé · Daniel Aletaha

Published online: January 4, 2023
© The Author(s) 2023

Correction to:
Rheumatology and Therapy
<https://doi.org/10.1007/s40744-022-00498-x>

In this article the legend for Fig. 5 was inadvertently with error, the legend for Fig. 5 should have appeared as shown below.

The original article can be found online at <https://doi.org/10.1007/s40744-022-00498-x>.

B. G. Combe (✉)
Montpellier University, Montpellier, France
e-mail: b-combe@chu-montpellier.fr

B. G. Combe
Rheumatology Department, Lapeyronie Hospital,
Montpellier University, 34295 Montpellier Cedex 5,
France

Y. Tanaka
The First Department of Internal Medicine,
University of Occupational and Environmental
Health, Kitakyushu, Japan

M. H. Buch
NIHR Manchester Biomedical Research Centre,
University of Manchester, Manchester, UK

P. Nash
Griffith University of Queensland, Brisbane,
Australia

G. R. Burmester
Charité University Hospital Berlin, Berlin, Germany

Fig. 5 LS mean CFB in mTSS among patients with any of the PPFs or four PPFs at A W24 or B W52. Each of the PPF subgroups [sero (+), hsCRP ≥ 6 , DAS28(CRP) > 5.1 , and erosion > 0] could include patients who also had other PPFs. * $P < 0.05$ versus PBO at W24; ** $P < 0.05$ versus ADA at W52. Comparison to ADA at W24 is out of scope for statistical calculation. All treatment groups also received methotrexate. ADA adalimumab, CFB change from baseline, DAS28(CRP) disease activity score for rheumatoid arthritis in

A. J. Kivitz
Altoona Center for Clinical Research, Duncansville,
PA, USA

B. Bartok · A. Pechonkina · K. Xia
Gilead Sciences, Inc., Foster City, CA, USA

K. Emoto · S. Kano
Gilead Sciences K.K., Tokyo, Japan

T. K. Hendriks
Galapagos NV, Mechelen, Belgium

R. B. M. Landewé
Amsterdam Rheumatology and Clinical
Immunology Center (amC) and Zuyderland MC,
Heerlen, The Netherlands

D. Aletaha
Medical University of Vienna, Vienna, Austria

28 joints with C-reactive protein, *FIL100* filgotinib 100 mg, *FIL200* filgotinib 200 mg, *hsCRP* high-sensitivity C-reactive protein, *LS* least squares, *mTSS* modified total Sharp score, *PBO* placebo, *PPF* poor prognostic factor, *Sero (+)* seropositivity for rheumatoid factor or anti-cyclic citrullinated peptide, *W* week.

The original article is updated accordingly.

OPEN ACCESS

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation,

distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.